Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Pennant Group ( (PNTG) ).
On October 1, 2025, The Pennant Group, Inc. and its subsidiaries amended a purchase agreement with UnitedHealth Group and Amedisys to acquire additional equity interests and assets related to home health, hospice, and palliative care services. The amendment increased the purchase price from $102,484,000 to $146,531,160 to reflect the acquisition of additional assets and entities, impacting the company’s operational scope and market positioning.
The most recent analyst rating on (PNTG) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Pennant Group stock, see the PNTG Stock Forecast page.
Spark’s Take on PNTG Stock
According to Spark, TipRanks’ AI Analyst, PNTG is a Outperform.
Pennant Group’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. While technical indicators show mixed signals, the company’s growth prospects and improved guidance provide a cautiously optimistic outlook. Valuation concerns and regulatory challenges are notable risks.
To see Spark’s full report on PNTG stock, click here.
More about Pennant Group
The Pennant Group, Inc. operates in the healthcare industry, focusing on providing home health, hospice, and palliative care services through its subsidiaries.
Average Trading Volume: 343,824
Technical Sentiment Signal: Sell
Current Market Cap: $877.9M
Find detailed analytics on PNTG stock on TipRanks’ Stock Analysis page.